Cannabics Pharmaceuticals Inc
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug… Read more
Cannabics Pharmaceuticals Inc (CNBX) - Total Liabilities
Latest total liabilities as of November 2025: $2.58 Million USD
Based on the latest financial reports, Cannabics Pharmaceuticals Inc (CNBX) has total liabilities worth $2.58 Million USD as of November 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cannabics Pharmaceuticals Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how Cannabics Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cannabics Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Cannabics Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qlosr Group AB Series B
ST:QLOSR-B
|
Sweden | Skr6.50 Million |
|
SASOL (SAOA.SG)
STU:SAOA
|
Germany | €232.31 Billion |
|
Anglesey Mining plc
F:4A0
|
Germany | €4.73 Million |
|
Archos
PA:ALJXR
|
France | €14.00 Million |
|
RABA (RMV1.SG)
STU:RMV1
|
Germany | €34.85 Billion |
|
Four Arrows Capital Corp
V:AROW-P
|
Canada | CA$21.37K |
Liability Composition Analysis (2005–2025)
This chart breaks down Cannabics Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 231.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cannabics Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cannabics Pharmaceuticals Inc (2005–2025)
The table below shows the annual total liabilities of Cannabics Pharmaceuticals Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | $2.51 Million | +0.13% |
| 2024-08-31 | $2.51 Million | -0.20% |
| 2023-08-31 | $2.52 Million | +2.98% |
| 2022-08-31 | $2.44 Million | +91.94% |
| 2021-08-31 | $1.27 Million | +179.92% |
| 2020-08-31 | $454.79K | +3.63% |
| 2019-08-31 | $438.87K | -18.63% |
| 2018-08-31 | $539.38K | -22.85% |
| 2017-08-31 | $699.12K | +42.34% |
| 2016-08-31 | $491.17K | +45.17% |
| 2015-08-31 | $338.33K | +356.34% |
| 2014-08-31 | $74.14K | -58.38% |
| 2013-08-31 | $178.15K | +263.63% |
| 2012-08-31 | $48.99K | +3.49% |
| 2011-08-31 | $47.34K | +35.30% |
| 2010-08-31 | $34.99K | -90.08% |
| 2009-08-31 | $352.69K | +20756.95% |
| 2008-08-31 | $1.69K | -93.76% |
| 2006-08-31 | $27.09K | -3.37% |
| 2005-08-31 | $28.04K | -- |